Last reviewed · How we verify

Health Research, Inc. — Portfolio Competitive Intelligence Brief

Health Research, Inc. pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Experimental Cyclic Regimen Experimental Cyclic Regimen marketed Small molecule Cardiovascular
Standard Clinical Practice Regimen Standard Clinical Practice Regimen marketed SSRI SERT, NET Psychiatry

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Akorn, Inc. · 1 shared drug class
  2. Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 1 shared drug class
  3. Astellas Pharma Inc · 1 shared drug class
  4. Beni-Suef University · 1 shared drug class
  5. Bristol-Myers Squibb · 1 shared drug class
  6. Centre of Clinical Pharmacology, Hanoi Medical University · 1 shared drug class
  7. Chonbuk National University Hospital · 1 shared drug class
  8. Abivax S.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Health Research, Inc.:

Cite this brief

Drug Landscape (2026). Health Research, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/health-research-inc. Accessed 2026-05-17.

Related